---
layout: category
title: Publication
---

**Jin C**, Chen M, Lin DY, Sun W (2021). Cell-type-aware analysis of RNA-seq data. *Nature Computational Science*. 1, 253â€“261. [Link to the publication.](https://www.nature.com/articles/s43588-021-00055-6) [Link to the preprint.](https://github.com/Sun-lab/CARseq/blob/master/inst/docs/Jin_et_al.-2021-Cell-type-aware_analysis_of_RNA-seq_data.pdf)

Lipner MB, Peng XL, **Jin C**, Xu Y, Gao Y, East MP, Rashid NU, Moffitt RA, Loeza SG, Morrison AB, Golitz BT, Vaziri C, Graves LM, Johnson GL, Yeh JJ (2020). Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. *JCI Insight*. 2020;5(8):e129905.

Rashid NU, Peng XL, **Jin C**, Moffitt RA, Volmar KE, Belt BA, Panni RZ, Nywening TM, Herrera SG, Moore KJ, Hennessey SG, Morrison AB, Kawalerski R, Nayyar A, Chang AE, Schmidt B, Kim HJ, Linehan DC, Yeh JJ (2020). Purity Independent Subtyping of Tumors (PurIST), A clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer. *Clinical Cancer Research*. *26*(1), 82-92.

Wilson DR, **Jin C**, Ibrahim JG, Sun W (2019). ICeD-T provides accurate estimates of immune cell abundance in tumor samples by allowing for aberrant gene expression patterns. *Journal of the American Statistical Association*, 1-11.

Sun W, **Jin C**, Gelfond JA, Chen M-H, Ibrahim JG (2019). Joint analysis of single-cell and bulk tissue sequencing data to infer intratumor heterogeneity. *Biometrics*, 1-12.

Sun W, Bunn P, **Jin C**, Little P, Zhabotynsky V, Perou CM, Hayes DN, Chen M, Lin DY (2018). The association between copy number aberration, DNA methylation and gene expression in tumor samples. *Nucleic Acids Research*, *46*(6), 3009-3018.

Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, Choi YJ, Sweeney KE, Suski JM, Yin H, Bogorad RL, Goel S, Yuzugullu H, Kauffman KJ, Yang J, **Jin C**, Li Y, Floris D, Swanson R, Ng K, Sicinka E, Anders L, Zhao JJ, Polyak K, Anderson DG, Li C, Sicinski P (2017). Cell-cycle-targeting microRNAs as therapeutic tools against refractory cancers. *Cancer Cell*, *31*(4), 576-590.

